Latest Adheron Therapeutics Stories
Adheron's lead product, Cadherin-11 inhibitor SDP051, is based on pioneering cell technology and may be used in various therapeutic indications of high unmet medical need SAN FRANCISCO, Jan. 8, 2014 /PRNewswire/ -- Adheron Therapeutics, a biotechnology company which focuses on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases, announced the completion of the company's Phase 1 clinical trial for its leading Cad-11 inhibitor SDP051. Cad-11...
- Exultant; jubilant; triumphant; on the high horse.
- Tipsy; slightly intoxicated.